menu
    • menu
    [{"orgOrder":0,"company":"eGenesis","sponsor":"Eledon Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Collaboration","leadProduct":"Tegoprubart","moa":"CD40 ligand","graph1":"Immunology","graph2":"Preclinical","graph3":"eGenesis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"eGenesis \/ Eledon Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"eGenesis \/ Eledon Pharmaceuticals"},{"orgOrder":0,"company":"eGenesis","sponsor":"University of Miami","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Collaboration","leadProduct":"HuCo Islet Cell","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"eGenesis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"eGenesis \/ University of Miami","highestDevelopmentStatusID":"4","companyTruncated":"eGenesis \/ University of Miami"},{"orgOrder":0,"company":"eGenesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"EGEN-2784","moa":"Undisclosed","graph1":"Nephrology","graph2":"IND Enabling","graph3":"eGenesis","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"eGenesis \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"eGenesis \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by eGenesis

    Menu

    eGenesis

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            eGenesis

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            eGenesis

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EGEN-2784

                            Therapeutic Area : Nephrology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            eGenesis Gets IND Clearance for EGEN-2784 in Kidney Transplant Study

                            Details : EGEN-2784 is a genetically engineered porcine-derived kidney, in patients with end stage kidney disease (ESKD).

                            Product Name : EGEN-2784

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            September 08, 2025

                            Lead Product(s) : EGEN-2784

                            Therapeutic Area : Nephrology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            eGenesis

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            eGenesis

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tegoprubart

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Eledon Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            eGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Preclinical Xenotransplan...

                            Details : AT-1501 (tegoprubart) is an investigational, humanized IgG1 anti-CD40L antibody with high affinity for the CD40 ligand. CD40L plays a pivotal role in immune system activation by mediating both antibody and cellular immune responses.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            January 09, 2023

                            Lead Product(s) : Tegoprubart

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Eledon Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            eGenesis

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            eGenesis

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HuCo Islet Cell

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : University of Miami

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            eGenesis Announces Research Collaboration with the University of Miami to Evaluate Human Compatible Islet Cell...

                            Details : The collaboration will encompass the evaluation of gene-edited pancreatic HuCo™ islet cells in a clinically relevant diabetes model as a prerequisite to advancing to human clinical trials.

                            Product Name : HuCo Islet Cells

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            March 09, 2022

                            Lead Product(s) : HuCo Islet Cell

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : University of Miami

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth